glecaprevir–pibrentasvir
Mavyret
Pharmaceutical company: AbbVie Inc.
NEW INDICATION & DOSAGE
Acute HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients who are treatment-naive without cirrhosis or with compensated cirrhosis (Child-Pugh class A)
Adults and children ages 12 and older or children ages 3 and older weighing at least 45 kg: 3 tablets (total daily dose of 300 mg glecaprevir/120 mg pibrentasvir) PO daily for 8 weeks.
Children ages 3 and older weighing 30 to less than 45 kg: 250 mg glecaprevir/100 mg pibrentasvir PO daily for 8 weeks.
Children ages 3 and older weighing 20 to less than 30 kg: 200 mg glecaprevir/80 mg pibrentasvir PO daily for 8 weeks.
Children ages 3 and older weighing less than 20 kg: 150 mg glecaprevir/60 mg pibrentasvir PO daily for 8 weeks.
Released: August 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
hydrocortisone
Khindivi
Pharmaceutical company: Eton Pharmaceuticals, Inc.
NEW BRAND
Khindivi
NEW FORM
Oral solution: 1 mg/mL
NEW INDICATION & DOSAGE
Replacement therapy in adrenocortical insufficiency
Children 5 years and older: 8 to 10 mg/m2/day (oral solution) in three divided doses. Higher doses may be needed based on child's age and disease symptoms. Individualize to lowest possible dose and round dose to nearest 0.5 or 1 mg. In older children, may divide daily dose into two doses.
Released: August 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
lenacapavir
Yeztugo
Pharmaceutical company: Gilead Sciences, Inc.
NEW INDICATION & DOSAGE
Pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1
Adults and adolescents weighing at least 35 kg: Day one, 927 mg (two 1.5 mL injections) subcut and 600 mg PO. Day two, 600 mg PO. Then, continue 927 mg subcut every 6 months from the date of last injection.
Adjust-a-dose: If scheduled injection is expected to be delayed by more than 2 weeks, may give 300 mg PO every 7 days for up to 6 months until injections resume. If more than 28 weeks pass since the last injection and tablets haven't been taken, reinitiate dosing from day 1. Refer to manufacturer's instructions for coadministration with moderate or strong CYP3A inducers.
Released: August 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
meloxicam
Xifyrm
Pharmaceutical company: Azurity Pharmaceuticals, Inc.
NEW FORM
Injection: 30 mg/mL single-dose vial
NEW INDICATION & DOSAGE
Management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics
Adults: 30 mg IV daily over 15 seconds. Use for shortest duration consistent with individual patient treatment goals.
Released: August 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
mepolizumab
Nucala
Pharmaceutical company: GlaxoSmithKline
NEW INDICATION & DOSAGE
Add-on maintenance treatment of inadequately controlled COPD in patients with an eosinophilic phenotype
Adults:100 mg subcut every 4 weeks.
Released: August 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
mitomycin
Zusduri
Pharmaceutical company: UroGen
NEW FORM
Intravesical solution: Kit containing two 40 mg single-dose vials mitomycin and one 60 mL vial sterile hydrogel for reconstitution
NEW INDICATION & DOSAGE
Recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
Adults: 75 mg (56 mL) instilled in bladder via urinary catheter once weekly for 6 weeks.
Released: August 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
pembrolizumab
Keytruda
Pharmaceutical company: Merck & Co., Inc.
NEW INDICATION & DOSAGE
Resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1 as a single agent neoadjuvant treatment and continued as adjuvant treatment
Adults: 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks or until unacceptable toxicity or disease progression precludes surgery. Continue as adjuvant treatment in combination with radiotherapy with or without cisplatin, and then as a single agent until disease recurrence or unacceptable toxicity, or up to one year.
Released: August 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
roflumilast
Zoryve
Pharmaceutical company: Arcutis Biotherapeutics
NEW FORM
Topical foam: 0.3%
NEW INDICATION & DOSAGE
Plaque psoriasis of the scalp and body
Adults and children age 12 and older:0.3% foam applied to affected areas daily.
Released: August 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.